title: [Pharmacological profile and clinical efficacy of human anti-human PD-1 antibody nivolumab (OPDIVO®) as a new immune checkpoint inhibitor].
authors.forename: Takao
authors.initials: T
authors.lastname: Yoshida
authors.forename: Kenichi
authors.initials: K
authors.lastname: Koda
authors.forename: Shintaro
authors.initials: S
authors.lastname: Nakao
authors.forename: Yukiya
authors.initials: Y
authors.lastname: Ohyama
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology*; D049109:Cell Proliferation; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy; D000077594:Nivolumab; D061026:Programmed Cell Death 1 Receptor / Q000276:immunology / Q000378:metabolism; D013601:T-Lymphocytes / Q000166:cytology / Q000187:drug effects / Q000276:immunology; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; D000077594:Nivolumab